ArticleFrontiers in pharmacology2022

Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation.

Xin Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.